Compass Therapeutics, Inc. (NASDAQ: CMPX) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Compass Therapeutics, Inc. (NASDAQ: CMPX) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $4.00 price target on the stock, down previously from $5.00.
Compass Therapeutics to Participate in Upcoming Investor Events
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.